Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
NCT06291376Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of ravulizumab in immunoglobulin A nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Mar 2024; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06291376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291376.